Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events

Publication | Closed Access

DOI

120

Citations

References

2020

Year

Alessio Cortellini, Melissa Bersanelli, Daniele Santini, Sebastiano Buti, Marcello Tiseo, Katia Cannita, Fabiana Perrone, Raffaele Giusti, Michele De Tursi, Federica Zoratto,

European Journal of Cancer

Cancer ImmunosurveillanceMedicineBody Mass IndexImmunologyImmunoeditingPathologyImmune Checkpoint InhibitorClinical OutcomesCancer PatientsCancer TreatmentImmunotherapyOncologyTumor MicroenvironmentCancer ResearchHealth Sciences